OpGen EBIT/Actif

Que fait OpGen ? OpGen, Inc. generates revenue through its Acuitas-branded high-resolution DNA tests and bioinformatics solutions, targeting healthcare providers and hospitals globally. The company's molecular diagnostics and informatics products help combat infectious diseases by providing precise diagnostic information on life-threatening infections and multidrug-resistant microorganisms. These solutions guide clinicians in managing patient outcomes and hospital biome protection through customized screening and surveillance. The firm's DNA tests and bioinformatics address antibiotic resistance, offering data-driven insights for healthcare decision-making. The company's Acuitas trade name is used for its high-resolution DNA tests, which are marketed to healthcare settings focused on infectious disease management. OpGen's products help hospitals manage patient care decisions and protect against the spread of infections caused by multidrug-resistant pathogens. The firm's global network of customers and partners includes healthcare providers seeking to implement pathogen surveillance systems for improved infection control. OpGen's business model centers on delivering molecular information solutions that combine DNA testing with bioinformatics, creating a comprehensive approach to infectious disease management. The company's focus on antibiotic resistance and multidrug-resistant microorganisms drives demand for its Acuitas products, which are positioned as tools for guiding clinical decisions and optimizing hospital infection control protocols. OpGen est l'une des entreprises les plus populaires sur Eulerpool.